|1.||Pei, Q: 2 articles (03/2004 - 01/2000)|
|2.||Garcia-Cairasco, N: 1 article (10/2015)|
|3.||de Oliveira Sergio, T: 1 article (10/2015)|
|4.||Glass, M L: 1 article (10/2015)|
|5.||Spiacci, A: 1 article (10/2015)|
|6.||da Silva, G S F: 1 article (10/2015)|
|7.||Zangrossi, H: 1 article (10/2015)|
|8.||Schenberg, L C: 1 article (10/2015)|
|9.||Sergio, T de Oliveira: 1 article (10/2015)|
|10.||MacSweeney, Cliona: 1 article (11/2014)|
|1.||Schizophrenia (Dementia Praecox)
01/01/2014 - "Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model."
01/01/2003 - "Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia."
11/01/1995 - "There is also evidence to suggest a role of serotonergic (5-HT) and glutamatergic systems in schizophrenia, and accordingly PPI can be disrupted by the 5-HT2 agonist DOI, and the non-competitive NMDA antagonist, dizocilpine. "
11/01/2014 - "The current in vitro and in vivo studies were undertaken to characterize the seizure potential of the potent and selective 5-HT2c agonist Org 306039. "
11/01/2014 - "Assessment of seizure liability of Org 306039, a 5-HT2c agonist, using hippocampal brain slice and rodent EEG telemetry."
11/01/2014 - "These results indicate that the in vitro and in vivo models complement each other in the characterization of the seizure potential of CNS-targeted compounds such as the 5-HT2c agonist Org 306039."
02/07/1997 - "We used 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), a 5-HT1A agonist, and 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), a 5-HT2 agonist, both of which were injected subcutaneously 15 min prior to each daily electrical stimulation to the rat AM. Treatment with 8-OH-DPAT (1 mg/kg) slightly suppressed behavioral and electrographic seizure development during the course of kindling. "
07/06/1992 - "This study assessed the effects of a serotonin (5-HT)1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), a 5-HT2 agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and a 5-HT2 antagonist ketanserin on fully kindled seizures from the hippocampus. "
03/01/1992 - "Specific esponse to 5-HT2 agonists by arterioles linked to Meth A tumors in mice."
07/01/1991 - "Hyper-responsiveness to 5-HT2 agonists by tumour-linked arterioles in mice: consequences for tumor growth."
03/01/1992 - "Using intravital microscopy, we compared the responses to serotonin [5-hydroxytryptamine (5-HT)] and to a specific 5-HT2 agonist [1-(2,5-dimethoxy-4-bromo-phenyl)-2-aminopropane (DOB)] by normal arterioles and by the host-modified arterioles feeding a Meth A tumor implanted into the flank of female BALB/c mice. "
|5.||Myoclonus (Nocturnal Myoclonus)
01/01/1993 - "Administration of a nonselective 5-HT agonist such as 5-MeODMT (5-HT1A/5-HT2 agonist) induces a dose-dependent behavior characterized by head jerking at low doses (1-2 mg/kg, SC) and full-blown myoclonus (continuous rhythmic whole-body jerking) at higher doses (2.5-5 mg/kg, SC). "
09/01/1995 - "The audiogenic posthypoxic myoclonus in these animals could be attenuated with the following drugs: 5-hydroxytryptophan (5-HTP, serotonin [5-HT] precursor), N-(3-trifluoro-methylphenyl)piperazine hydrochloride (TFMPP, 5-HT1B/1C/2 agonist), (+/-)-2,5-dimethoxy-4-iodoamphetamine hydrobromide (DOI, 5-HT2 agonist), and 1-(m-chlorophenyl)-biguanide hydrochloride (m-CPBG, 5-HT3 agonist). "
|1.||Serotonin (5 Hydroxytryptamine)
|5.||Serotonin 5-HT2 Receptor Antagonists
|6.||Serotonin 5-HT1 Receptor Agonists
|8.||Messenger RNA (mRNA)